

# A Review on Pharmacovigilance

Mrunalini Unecha<sup>1</sup>, Ajay Sabale<sup>2</sup>, Prof. Santosh Waghmare<sup>3</sup>, Dr. Hemant Kamble<sup>4</sup>

<sup>1</sup>Student, Department of Pharmaceutics

<sup>2</sup>Student, Department of Pharmacology

<sup>3</sup>Professor, Department of Pharmacy

<sup>4</sup>Principle, Department of Pharmacy

<sup>1,2,3,4</sup>Loknete Shri Dadapatil Pharate College of Pharmacy, Shirur, Pune, Maharashtra

**Abstract:** *Pharmacovigilance defined by the world health organization as "the science and activities relating to the detection, assessment, understanding, assessment and prevention of adverse effects or any other drug related problems". It plays a key role in ensuring that patients receive safe drugs. Our knowledge of a drug's adverse reactions can be increased by various means, including spontaneous reporting, intensive monitoring and database studies. New processes both at a regulatory and scientific level are being developed with the aim of strengthening pharmacovigilance. On a regulatory level transparency and increased patient involvement are two important elements.*

**Keywords:** Drug regulation, Drug safety, Intensive monitoring, Pharmacovigilance, Spontaneous reporting, Transparency

## REFERENCES

- [1]. World health organization collaborating centre for international drug monitoring (2007). The importance of pharmacovigilance available at [http://www.who\\_umc.org](http://www.who_umc.org) cited 18 December 2007.
- [2]. Lazarou J, Pomeranz BH, Corey PN; Incidence of Adverse Drug Reactions in hospitalized patients. JAMA, 198; 279: 1200-1205.
- [3]. Bord CA, Rachi CL; Adverse Drug Reactions in United States Hospitals. Pharmacotherapy, 2006; 26(5): 601-08.
- [4]. World Health Organization(WHO), Uppsala Monitoring Centre(internet). The use of WHO-UMC system for standard case causality assessment available at <http://www.who-umc.org/graphics/4409.pdf>.
- [5]. Macedo AF, Marques FB, Ribeiro CF, Texeira F. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. Pharmacoepidemiological drug sof., 2005; 14: 885-890.
- [6]. Arimone Y, Begnad B, Miremont, Salame G, Fourrier-Regalt A, Moore N, Molimard M et al, agreement of expert judgment in causality assessment of adverse drug reactions. Eur J Clin pharmacology, 2005; 61: 169-173.
- [7]. Joerg H. Basic principles of pharmacovigilance and data sources.
- [8]. Sachdev Y. pharmacovigilance: safety matters, Indian pharmacology. February 2008; 40.
- [9]. Hall et al. 1995; Horbuckle et al. 1999; Tuntti and Neuroren 2002.
- [10]. Moore N (2001). The role of clinical pharmacologist in management of ADRs. Drug safety, 211(1): 1-7.
- [11]. The importance of pharmacovigilance; safety monitoring of medical products, Geneva, WHO, 2002.
- [12]. J.P Loannidis, J Lau. Completeness of safety reporting in randomized trials: an evaluation of seven medical areas. JAMA, 2001; 285(4): 437-443.
- [13]. P.Biswas, A. K. Biswas setting standards for proactive pharmacovigilance in India: the way forward. Indian Journal of pharmacology, 2007; 39: 124-128.
- [14]. Ronald M, Elizabeth BA.
- [15]. Moore N. The role of clinical pharmacologist in the management of ADRs. Drug safety, 2001; 24(1): 1-7.
- [16]. Hall M, Mc Cormack P, Aurther N, Feely J. The spontaneous reporting of ADRs by nurses. British journal of clinical pharmacology, 1995; 40: 173-175.

- [17]. Hornbuckle K, WUH-H, Fung MC. Evaluation of spontaneous adverse event of reports by primary reporter a 15 year review (1983-1997). Drug information journal of clinical pharmacology, 1995; 40: 173-175.
- [18]. Consumer reporting ADRs. WHO drug information, 2000; 14: 211-215.
- [19]. Egberts GPG Smulderes M, De Konig FHP et al. Can ADRs be detected earlier? A comparison of reports by patients and professionals. British Medical Journal, 1996; 313: 530-531.